Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Bio-process Technology Market Size and Share Analysis 2023-2028
The Bio-process Technology Market is projected to experience substantial growth, increasing from USD 29,365 million in 2023 to USD 57,639 million by 2028, with a compound annual growth rate (CAGR) of 14.44% during the forecast period (2023-2028).
The emergence of the COVID-19 pandemic has had a significant impact on various industries, including the bioprocess technology market. The initial phase of the pandemic caused major disruptions and hindered the growth of the market. For example, in August 2022, an article published in the American Pharmaceutical Review highlighted the strain on supply chains in the biopharmaceutical manufacturing industry. The production of essential consumable goods, such as membrane filters used for sterilization and other purposes in bioprocessing, experienced critical shortages. Additionally, single-use systems, separation columns, tubing, raw materials, and components were not readily available. Despite these challenges, the market is expected to regain momentum due to the urgent need for vaccine and biological product development. According to an article published by Poznan University of Economics and Business, biopharmaceutical companies formed new partnerships to expedite the discovery and delivery of COVID-19 vaccines. The pandemic has also spurred the development of innovative projects related to vaccine and drug development, with bioprocess technology playing a crucial role in the production of vaccines and other biopharmaceuticals.
|No. of Pages||
USD 26.1 billion in 2021
Product, Application, End User, and Geography
|No. of Companies Mentioned||
The growth of the bioprocess technology market is primarily driven by the expansion of the biopharmaceutical industry and increased investments in research and development (R&D) by biotechnology and pharmaceutical companies. The biopharmaceutical sector has become deeply integrated into the medical and pharmaceutical industries as pharmaceutical companies transition towards biotechnology, creating growth opportunities. Technological advancements in biopharmaceutical and pharmaceutical sectors, such as 3D bioprinting, biosensors, gene editing, and the incorporation of artificial intelligence, virtual reality, and augmented reality, are expected to enhance and accelerate production through bioprocessing, as stated in a report published in the Biotechnology Report in July 2022. Consequently, the demand for bio-process technology is increasing, fueling market growth.
Furthermore, partnerships and agreements between biopharmaceutical companies, aimed at developing innovative products, are contributing to market expansion. For instance, in October 2022, Oculis SA and European Biotech Acquisition Corp. announced a definitive business combination agreement to expedite the development of Oculis’ differentiated ophthalmology pipeline. This pipeline addresses significant medical needs in conditions such as diabetic macular edema, dry eye disease, and neuro-retina indications like glaucoma, which affect growing patient populations.
Increasing investments in research and development are also playing a significant role in driving market growth. The biopharmaceutical industry consistently outpaces other industrial sectors in R&D spending, as highlighted in a report by the International Federation of Pharmaceutical Manufacturers & Associations. The industry’s annual R&D spending is 8.1 times greater than the aerospace and defense industries, 7.2 times more than the chemicals industry, and 1.2 times more than the software and computer services industry. Even during times of economic turmoil and financial crisis, the biopharmaceutical industry remains committed to R&D investment. For instance, Thermo Fisher Scientific’s 2021 annual report revealed a research and development cost of USD 1,406.00 million in 2021, with a growth rate of 19.05%. The increased R&D expenses of biopharmaceutical companies contribute to the development of innovative biopharma products, further driving market growth.
In conclusion, the bio-process technology market is poised for significant growth due to the expansion of the biopharmaceutical industry and increased investments in research and development by biotechnology and pharmaceutical companies. However, the high cost of instruments and stringent regulations may hinder the growth of the market during the forecast period.
The market is segmented based on various factors, including product, application, end user, and geography.
Segmentation by Product
Instruments – Bioprocess Analyzers, Osmometers, Bioreactors, Incubators, Other Instruments
Consumables and Accessories – Culture Media, Reagents, Other Consumables and Acessories
Segmentation by Application
Segmentation by End User
Contract Manufacturing Organizations
Academic Research Institute
Segmentation by Geography
North America – United States, Canada, Mexico
Europe – United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America – Brazil, Argentina, and Rest of Latin America
Middle East and Africa – GCC, South Africa, and Rest of Middle East and Africa
The consumables and accessories segment is poised for growth in the bio-process technology market. This growth is primarily driven by the increasing demand for reagents in healthcare settings and laboratories for testing target patients. In 2022, the consumables and accessories segment held the largest market share, amounting to USD 15,869 million. It is projected to experience a compound annual growth rate (CAGR) of 14.03% over the forecast period.
Reagents play a crucial role in cell-based products, pharmaceutical drug manufacturing and testing, and various healthcare-related solutions. The demand for reagents is expected to rise in healthcare settings and laboratories as they are instrumental in testing target patients. Moreover, researchers utilize reagents to study disease epidemiology, further contributing to the growth of this segment.
The monoclonal antibodies segment is also anticipated to witness growth due to increasing research and development activities related to monoclonal antibodies.
The industrial synthesis of recombinant proteins, which are vital for therapeutic and preventive purposes, relies on effective bioprocessing techniques. Advancements in bioprocessing methods are being made to create recombinant proteins more efficiently. These advancements include the use of high-throughput devices for bioprocess optimization, disposable systems, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, quality by design, and process analytical technologies. These developments aim to produce high-quality products with higher yields. The recombinant protein segment is expected to experience significant growth as the demand for recombinant proteins for therapeutic applications continues to rise. These proteins offer essential therapies for various diseases such as diabetes, cancer, infectious diseases, hemophilia, and anemia. Furthermore, recombinant proteins are valuable tools in studying protein-protein interactions, and the continuous research and technological advancements in this field are anticipated to drive segment growth.
For example, Larimar Therapeutics Inc. recently obtained a US patent for CTI-1601, a recombinant fusion protein designed to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia. This innovation showcases the potential of recombinant proteins in treating genetic disorders. Similarly, in February 2021, Sanofi and GSK initiated a Phase 2 study for their adjuvanted recombinant protein-based COVID-19 vaccine, demonstrating the ongoing development of recombinant protein-based drugs. The rising prevalence of chronic diseases like diabetes further contributes to the demand for recombinant proteins, as reported by the International Diabetes Federation (IDF). The number of diabetics worldwide is expected to increase significantly, thereby driving the demand for recombinant proteins in therapeutic applications.
The biopharmaceutical company segment is expected to grow due to increased research and development spending in this sector. Bioprocessing and pharmaceutical industries aim to enhance manufacturing flexibility, speed to market, and meet stringent quality assurance requirements. The biopharmaceutical industry’s annual research and development spending surpasses that of other industries such as aerospace and defense, chemicals, and software and computer services.
In terms of geographical growth, North America is projected to experience rapid expansion in the bio-process technology market. This growth is attributed to government support for promoting bioprocess technologies, increased healthcare expenditure, and the development of healthcare infrastructure. Collaborative activities between healthcare giants and investments in research and development further contribute to the growth of this region. For instance, Stam Biotech secured USD 17 million for its next-generation 3-D printer bioreactor, Thermo Fisher Scientific Inc. launched a large-scale cell culture harvesting solution, and GOOD Meat entered into an exclusive agreement with ABEC Inc. to develop the largest known bioreactors for avian and mammalian cell culture. These advancements and collaborations by major biopharmaceutical companies in North America drive the growth of the bioprocess technology market in this region.
In summary, the bio-process technology market is witnessing growth in the consumables and accessories segment, driven by the demand for reagents in healthcare settings and laboratories. The monoclonal antibodies segment is also expected to grow due to increased research and development efforts. The recombinant protein segment is projected to witness significant growth, fueled by the rising demand for therapeutic applications and ongoing technological advancements. The biopharmaceutical company segment is anticipated to expand due to increased research and development spending. North America is poised for rapid growth in the market, supported by government initiatives, healthcare expenditure, and collaborative activities with major industry players.
The bio-process technology market exhibits fragmentation and competitiveness, primarily attributed to the presence of numerous companies operating on a global and regional scale. The competitive landscape encompasses an analysis of both international and local companies that possess significant market shares and enjoy widespread recognition.
Key companies profiled in this report include F. Hoffmann-La Roche Ltd, Sartorius Group, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Elitechgroup SpA (Gonotec Gmbh), Advanced Instruments LLC, Danaher Corporation, Merck KGaA, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Lonza Group AG, Sartorius Group.
Recent Industry Developments
In February 2023, a team of researchers from the Indian Institute of Technology (IIT) Guwahati has successfully developed a specialized ‘Protein Toolbox.’ This innovative toolbox has the capability to convert skin cells into heart cells, offering a potential solution for repairing damaged hearts. Referred to as the ‘Recombinant Protein Toolbox,’ it consists of six unique proteins and can effectively regenerate damaged heart tissues.
In August 2022, Beckman Coulter Life Sciences announced a collaborative partnership with Flownamics to develop an automated and online solution for monitoring and controlling bioprocess cultures. This collaboration aims to eliminate the potential for errors associated with manual steps, while also enabling convenient sample runs for up to eight bioreactors. The integration of this automated system ensures compliance with Good Manufacturing Practices (GMP) through electronic data management. Moreover, it provides continuous control over viable cell density, including the ability to remotely manage workflows.
Key Questions Answered
How large is the Bio-process Technology Market?
The Bio-process Technology Market is expected to reach a size of USD 29,365 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 14.44% to reach USD 57,639 million by 2028.
What is the current size of the Bio-process Technology Market?
The Bio-process Technology Market is expected to reach a size of USD 29,365 million in 2023.
Who are the key players in the Bio-process Technology Market?
The major companies operating in the Bio-process Technology Market are Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., and Sartorius Group.
Which region is experiencing the fastest growth in the Bio-process Technology Market?
The Asia Pacific region is estimated to have the highest compound annual growth rate (CAGR) over the forecast period (2023-2028) in the Bio-process Technology Market.
Which region has the largest market share in the Bio-process Technology Market?
In 2023, North America accounts for the largest market share in the Bio-process Technology Market.